A functional analysis of protooncogene Vav's role in adult human hematopoiesis

Blood

Volumn 87, Issue 4, 1996, Pages 1326-1334

  Luger, Selina M ^a   Ratajczak, Janina ^a   Ratajczak, Mariusz Z ^a   Kuczynski, Wojech I ^a   DiPaola, Robert S ^a   Ngo, Winnie ^a   Clevenger, Charles V ^a   Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; OLIGODEOXYNUCLEOTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; BURST FORMING UNIT E; CELL MATURATION; CHRONIC MYELOID LEUKEMIA; CODON; COLONY FORMING UNIT GM; ERYTHROID CELL; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MONONUCLEAR CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030049003     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.4.1326.bloodjournal8741326     Document Type: Article

References (43)

1. Katzav S, Martin-Zanca D, Barbacid M: vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 8:2283, 1989
2. Alai M, Mui AL, Cutler RL, Bustelo XR, Barbacid M, Krystal G: Steel factor stimulates the tyrosine phosphorylation of the protooncogene product, p95vav, in human hemopoietic cells. J Biol Chem 267:18021, 1992
3. Galland F, Katzav S, Birnbaum D: The products of the mcf-2 and vav proto-oncogenes and of the yeast gene cdc-24 share sequence similarities. Oncogene 7:585, 1992
4. Cen H, Papageorge AG, Zippel R, Lowy DR, Zhang K: Isolation of multiple mouse cDNAs with coding homology to Saccharomyces cerevisiae CDC25: identification of a region related to Bcr, Vav, Dbl and CDC24 EMBO J 11:4007, 1992
5. Katzav S, Cleveland JL, Heslop HE, Pulido D: Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol 11:1912, 1991
6. Coppola J, Bryant S, Koda T, Conway D, Barbacid M: Mechanism of activation of the vav protooncogene. Cell Growth Differ 2:95, 1991
7. Adams JM, Houston H, Allen J, Lints T, Harvey R: The hematopoietically expressed vav proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization. Oncogene 7:611, 1992
8. Musacchio A, Gibson T, Rice P, Thompson J, Saraste M: The PH domain: A common piece in the structural patchwork of signaling proteins. Trends Biochem Sci 18:343, 1993
9. Feig LA: The many roads that lead to Ras [comment]. Science 260:767, 1993
10. Clevenger CV, Ngo W, Sokot DL, Luger SM, Gewirtz AM: Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. J Biol Chem 270:13246, 1995
11. Hu P, Margolis B, Schlessinger J: Vav: A potential link between tyrosine kinases and ras-like GTPases in hematopoietic cell signaling Bioessays 15:179, 1993
12. Boguski MS, Bairoch A, Attwood TK, Michaels GS: Protovav and gene expression [letter; comment]. Nature 358:113, 1992
13. Hobert O, Jallal B, Schlessinger J, Ullrich A: Novel signaling pathway suggested by SH3 domain-mediated p95vav/heterogeneous ribonucleoprotein K interaction. J Biol Chem 269:20225, 1994
14. Bustelo XR, Suen KL, Michael WM, Dreyfuss G, Barbacid M: Association of the vav proto-oncogene product with poly(rC)-specific RNA-binding proteins. Mol Cell Biol 15:1324, 1995
15. Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, Weiss A, Schlessinger J: Tyrosine phosphorylation of vav protooncogene product containing SH2 domain and transcription factor motifs [see comments]. Nature 356:71, 1992
16. Bustelo XR, Barbacid M: Tyrosine phosphorylation of the vav proto-oncogene product in activated B cells. Science 256:1196, 1992
17. Platanias LC, Sweet ME: Interferon alpha induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells. J Biol Chem 269:3143, 1994
18. Matsuguchi T, Inhorn RC, Carlesso N, Xu G, Druker B, Griffin JD: Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J 14:257, 1995
19. Dosil M, Wang S, Lernischka IR: Mitogenic signaling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 13:6572, 1993
20. Gulbins E, Coggeshall KM, Langlet C, Baier G, Bonnefoy-Berard N, Burn P, Wittinghofer A, Katzav S, Altman A: Activation of Ras in vitro and in intact fibroblasts by the Vav guanine nucleotide exchange protein. Mol Cell Biol 14:906, 1994
21. Khosravi-Far R, Chrzanowska-Wodnicka M, Solski PA, Eva A, Burridge K, Der CJ: Dbl and Vav mediate transformation via mitogen-activated protein kinase pathways that are distinct from those activated by oncogenic Ras. Mol Cell Biol 14:6848, 1994
22. Gulbins E, Coggeshall KM, Baier G, Katzav S, Burn P, Altman A: Tyrosine kinase-stimulated guanine nucleotide exchange activity of Vav in T cell activation [see comments]. Science 260:822, 1993
23. Gulbins E, Langlet C, Baier G, Bonnefoy-Berard N, Herbert E, Altman A, Coggeshall KM: Tyrosine phosphorylation and activation of Vav GTP/GDP exchange activity in antigen receptor-triggered B cells. J Immunol 152:2123, 1994
24. Bustelo XR, Suen KL, Leftheris K, Meyers CA, Barbacid M: Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene 9:2405, 1994
25. Wulf GM, Adra CN, Lim B: Inhibition of hematopoietic development from embryonic stem cells by antisense vav RNA. EMBO J 12:5065, 1993
26. Zhang R, Tsai FY, Orkin SH: Hematopoietic development of vav-/-mouse embryonic stem cells. Proc Natl Acad Sci USA 91:12755, 1994
27. Zmuidzinas A, Fischer KD, Lira SA, Forrester L, Bryant S, Bernstein A, Barbacid M: The vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J 14:1, 1995
28. Zhang R, Alt FW, Davidson L, Orkin SH, Swat W: Defective signaling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature 374:470, 1995
29. Gewirtz AM, Calabretta B: A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 242:1303, 1988
30. Ratajczak MZ, Kuczynski WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, DeRiel K, Gewirtz AM: A reappraisal of the role of insulin-like growth factor I in the regulation of human hematopoiesis. J Clin Invest 94:320, 1994
31. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79:1956, 1992
32. Ratajczak MZ, Luger SM, DeRiel K, Abrahm J, Calabretta B, Gewirtz AM. Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci USA 89:1710, 1992
33. Caracciolo D, Venturelli D, Valtieri M, Peschle C, Gewirtz AM, Calabretta B: Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest 85:55, 1990
34. Ramos-Morales F, Druker BJ, Fischer S: Vav binds to several SH2/SH3 containing proteins in activated lymphocytes. Oncogene 9:1917, 1994
35. Bustelo XR, Rubin SD, Suen KL, Carrasco D, Barbacid M: Developmental expression of the vav protooncogene. Cell Growth Differ 4:297, 1993
36. Evans GA, Howard OM, Erwin R, Farrar WL: Interleukin-2 induces tyrosine phosphorylation of the vav proto-oncogene product in human T cells: Lack of requirement for the tyrosine kinase lck. Biochem J 294:339, 1993
37. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, Orkin SH: Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81:695, 1995
38. Hanazono Y, Sasaki K, Odai H, Mimura T, Mitani K, Yazaki Y, Hirai H: Tyrosine phosphorylation of the proto-oncogene product Vav and its association with the adapter Grb2/Ash in a human leukemia cell line UT-7. Jpn J Cancer Res 86:336, 1995
39. Tarakhovsky A, Turner M, Schaal S, Mee PJ, Duddy LP, Rajewsky K, Tybulewicz VL: Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374:467, 1995
40. Broxmeyer HE: Growth factors and cord blood stem and progenitor cells. Immunol Invest 24:391, 1995
41. Dracker RA: Hematopoietic stem cells: Form - method - characteristics. Immunol Invest 24:443, 1995
42. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261:1004, 1993
43. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333, 1994